Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007

被引:47
作者
Currie, C. J. [1 ]
Gale, E. A. M. [2 ]
Poole, C. D. [3 ]
机构
[1] Cardiff Univ, Sch Med, Pharma Res Ctr, Cardiff MediCtr,Dept Med, Cardiff CF14 4UJ, S Glam, Wales
[2] Univ Bristol, Sch Med, Bristol, Avon, England
[3] Worldwide Epidemiol, Cardiff, Wales
基金
英国医学研究理事会; 英国工程与自然科学研究理事会;
关键词
cost effectiveness; diabetes; prescribing; resource use; trend; RISK; UK; VALIDATION; MELLITUS; HBA(1C);
D O I
10.1111/j.1464-5491.2010.03040.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Aims The purpose of this study was to characterize the financial cost and efficacy of primary care treatment for diabetes in the United Kingdom from 1997 to 2007. Methods Retrospective data were analysed for people with Type 1 and Type 2 diabetes along with matched control subjects using data from The Health Improvement Network. Costs were attributed from published sources and adjusted for price inflation. Type 2 diabetes was analysed by five commonly used treatment regimens. Results It was possible to identify 126 052 people for inclusion: 11 300 (8.9%) with Type 1 diabetes and 114 752 (91.1%) with Type 2. The overall mean prescribing costs per person per year (pppy) increased markedly for people with diabetes from 1997 to 2007: for Type 1, from 573 pound to 1014 pound pppy (+77%), and for Type 2, from 39 pound to 740 pound pppy (+89%). In 2007, diabetes-treatment-specific prescribing represented 57% of prescribing costs in Type 1 diabetes and 28% in Type 2 diabetes. In Type 2 diabetes there was a mean of 5.4 primary care consultations in 1997, increasing to 11.5 pppy in 2007 (+112%). In 1997 the total mean cost of primary care treatment for Type 2 diabetes was 602 pound pppy, increasing to 1080 pound in 2007. In Type 1 diabetes, the mean glycated haemoglobin decreased by 0.1% from 8.8% in 2001 to 8.7% in 2007; the corresponding change using insulin in Type 2 diabetes was also 0.1%. Greater improvement in blood pressure and lipids was evident. Conclusions Over the 10 year period to 2007, diabetes-related primary care adjusted costs increased considerably, whereas glycated haemoglobin values did not improve at all over the same period.
引用
收藏
页码:938 / 948
页数:11
相关论文
共 24 条
  • [1] [Anonymous], National Diabetes Audit Executive Summary 2009-2010
  • [2] [Anonymous], 2007, Unit Costs of Health and Social Care
  • [3] The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060
    Bagust, A
    Hopkinson, PK
    Maslove, L
    Currie, CJ
    [J]. DIABETIC MEDICINE, 2002, 19 : 1 - 5
  • [4] The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus
    Burke, Thomas A.
    Sturkenboom, Miriam C.
    Ohman-Strickland, Pamela A.
    Wentworth, Charles E.
    Rhoads, George G.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (09) : 979 - 987
  • [5] The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings
    Currie, C. J.
    [J]. DIABETOLOGIA, 2009, 52 (10) : 2234 - 2235
  • [6] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    Currie, C. J.
    Poole, C. D.
    Gale, E. A. M.
    [J]. DIABETOLOGIA, 2009, 52 (09) : 1766 - 1777
  • [7] Currie CJ, 1997, DIABETIC MED, V14, P686, DOI 10.1002/(SICI)1096-9136(199708)14:8<686::AID-DIA434>3.0.CO
  • [8] 2-D
  • [9] CURRIE CJ, 2008, DIABETIC MED, V27, P744
  • [10] Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
    Currie, Craig J.
    Peters, John R.
    Tynan, Aodan
    Evans, Marc
    Heine, Robert J.
    Bracco, Oswaldo L.
    Zagar, Tony
    Poole, Chris D.
    [J]. LANCET, 2010, 375 (9713) : 481 - 489